Compare Nasdaq Inc (NDAQ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Nasdaq Inc trades at $93.65 (market cap $51.63B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Nasdaq Inc is far larger — about 5.1× State Street SPDR S&P Biotech ETF's market cap, and Nasdaq Inc pays a 1.26% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq Inc for 126 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| NDAQ | XBI | |
|---|---|---|
Market Cap | $51.63B | $10.11B |
Volume | 2,668,175 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $100.98 | $169.55 |
52-Week Low | $76.85 | $104.99 |
Typical Hold Time | 126 Days | 38 Days |
Enterprise Value | $58.09B | — |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq Inc. (NDAQ) trades at $92.37, up 0.48% today, with a bullish technical signal from moving averages and strong fundamental performance including a 21.64% net income margin and consistent earnings beats. Recent news highlights growth in its Financial Technology business, such as HSBC adopting Nasdaq Calypso for derivatives clearing (GlobeNewsWire, 2026-09-28).
The outlook is positive with a consensus price target of $110.43, implying 19.6% upside, supported by robust profitability and AI-driven initiatives. Risks include high valuation multiples and market volatility, but analyst sentiment is strongly bullish with 61% buy ratings.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
